Highlights

  • Product sales increased 42% year over year as TruScreen expanded into new markets.
  • A major cervical cancer screening programme in Vietnam and renewed entry into India strengthened growth prospects.
  • New distributor appointments and UNITAID proposals expanded access to high-burden screening markets globally.

Overview

TruScreen Group Limited (NZX:TRU) reported significant commercial progress during FY2026 as it expanded its global footprint and increased product sales by 42% year over year. The company advanced its cervical cancer screening strategy through new market entries, distributor appointments, and participation in large-scale public health initiatives. Key milestones included the launch of a major screening programme in Vietnam, re-entry into India, and expanded opportunities across Africa, Asia, and Latin America. Clinical validation studies continued to support the effectiveness of TruScreen’s AI-enabled technology, while investments in market development and public screening programmes positioned the company for broader adoption and future Revenue growth.

What Drove TruScreen’s Growth During FY2026?

TruScreen’s performance was supported by growing Demand for its cervical cancer screening technology across both existing and new markets. The company generated sales from a wider geographic base, including initial commercial activity in India and Indonesia. China remained its largest contributor, while expanding adoption in Vietnam helped strengthen regional momentum.

Clinical studies published during the year reinforced the effectiveness of TruScreen’s technology, supporting its position as a primary screening option in underserved healthcare settings. These developments helped strengthen relationships with healthcare providers, regulators, and public health organisations globally.

How Is TruScreen Expanding Its Global Opportunity?

The company continued building its international presence through new distributor partnerships and participation in public health initiatives targeting cervical cancer prevention. During FY2026, TruScreen expanded into several new countries while progressing regulatory approvals across key markets.

The company also submitted proposals covering multiple high-burden countries through global screening initiatives, creating access to a large addressable patient population. Combined with ongoing clinical programmes and market-entry activities across Asia, Africa, and Latin America, these efforts are expected to support future commercial growth and broader adoption of the TruScreen platform.